Search

Takeda Pharmaceutical Co Ltd ADR

Gesloten

SectorGezondheidszorg

20.87 -0.29

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.89

Max

20.93

Belangrijke statistieken

By Trading Economics

Inkomsten

138B

113B

Verkoop

105B

1.2T

K/W

Sectorgemiddelde

42.622

50.373

EPS

0.48

Dividendrendement

3.05

Winstmarge

9.279

Werknemers

47,029

EBITDA

231B

389B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+106.37% upside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

3.05%

2.12%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

9.6B

65B

Vorige openingsprijs

21.16

Vorige sluitingsprijs

20.87

Takeda Pharmaceutical Co Ltd ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 nov 2026, 13:01 UTC

News

Michael Saylor plans to purchase additional Bitcoin, aiming to exceed 850k BTC for the first time.

31 okt 2026, 00:02 UTC

News

Lyft, Inc. shares are advancing in after-market trading, supported by a broader market uptick.

31 okt 2026, 00:02 UTC

Social Media
Correlated Moves
News

MSCI Inc. will continue using regular trading hours closing prices for index calculations, despite updates on trading extensions from Nasdaq and NYSE Arca.

31 okt 2026, 00:02 UTC

Correlated Moves
News

Cantor Fitzgerald identifies buying opportunity in crypto-linked stocks, including Strategy Inc, following Binance hack, noting potential for recovery as panic subsides.

31 okt 2026, 00:02 UTC

Correlated Moves
News

Allegro Microsystems Inc reported Q2 FY27 sales of $276.88 million and net income of $23.26 million, with shares trading higher in after-market hours.

31 okt 2026, 00:02 UTC

News

Okta, Inc. will replace Kenvue in the S&P 500 on November 4, 2026, following Kimberly-Clark's acquisition, enhancing its visibility to investors.

31 okt 2026, 00:02 UTC

News

DICK'S Sporting Goods faces class action lawsuits alleging securities fraud and misleading investors about financial performance following an earnings miss.

31 okt 2026, 00:02 UTC

News
Social Media

Coinbase Global, Inc. saw an uptick in after-market trading after JP Morgan maintained its Overweight rating but lowered the price target to $187.

31 okt 2026, 00:01 UTC

News

Mondelez International, Inc. shares traded modestly lower during after-market hours on Friday, following a decline from a brief peak earlier in the session.

31 okt 2026, 00:01 UTC

News

Kimberly-Clark Corporation is set to acquire Kenvue, with the transaction expected to close soon, subject to final conditions.

31 okt 2026, 00:01 UTC

News

Kraft Heinz Company shares advanced in after-market trading, reaching their highest point since Friday's close and trading near the upper end of their one-month range.

31 okt 2026, 00:01 UTC

News

BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in its share price during after-market hours.

31 okt 2026, 00:01 UTC

News

Ares Capital Corporation announced a merger agreement to acquire MidCap Financial Investment Corporation, resulting in the cancellation of MidCap's earnings call on November 5, 2026.

31 okt 2026, 00:01 UTC

News

BWX Technologies Inc is rising in after-market trading after being selected by the U.S. Army to develop a nuclear microreactor for its $2.2 billion Janus program.

30 okt 2026, 23:51 UTC

News

FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.

30 okt 2026, 23:51 UTC

News

BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.

30 okt 2026, 23:51 UTC

News

Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.

30 okt 2026, 23:41 UTC

News

Allegro Microsystems Inc. reported Q2 FY27 sales of $276.88M, exceeding expectations, and provided Q3 guidance of $278M to $288M, with shares modestly higher in after-market trading.

30 okt 2026, 23:41 UTC

News

BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in the stock's price during after-market hours.

30 okt 2026, 23:36 UTC

News

Capri Holdings Ltd reported Q2 profit of 42 cents per share and raised full-year EPS forecast to $2.20, with shares trading lower in after-market hours.

30 okt 2026, 23:31 UTC

News

McGrath RentCorp will replace Glaukos in the S&P 600 index at the market open on November 4, 2026, contributing to positive after-market price movement.

30 okt 2026, 23:26 UTC

News

JP Morgan maintains its Underweight rating on T. Rowe Price while raising the price target to $107; TD Cowen lowers its target to $96.

30 okt 2026, 23:26 UTC

News

Citigroup reaffirms Buy rating on Fortrea Holdings Inc and raises price target to $27, according to a report published today.

30 okt 2026, 23:21 UTC

News

Compass Inc. faces a class action lawsuit from Pomerantz LLP, alleging securities fraud related to its merger with Anywhere Real Estate Inc.

30 okt 2026, 23:16 UTC

News

JP Morgan maintains Neutral rating on Dexcom Inc and raises its price target to $85, reflecting the company's market position and growth potential.

30 okt 2026, 23:11 UTC

News

Pomerantz LLP has filed a class action lawsuit against The Chemours Company, alleging misleading statements and violations of federal securities laws.

30 okt 2026, 23:11 UTC

News

Cantor Fitzgerald identifies Binance's $6.3 billion hack as a potential buying opportunity for crypto-linked stocks, including Strategy Inc., amid recovery confidence.

30 okt 2026, 23:06 UTC

News

Uranium Energy Corp. shares declined in after-market hours, reflecting broader sector pressures despite analysts noting tightening supply in the uranium market.

30 okt 2026, 23:06 UTC

News
Social Media

S&P Global Ratings revised its outlook on Meta Platforms, Inc. to negative, citing uncertainty over capital expenditures and projected free operating cash flow deficits.

30 okt 2026, 23:06 UTC

News
Social Media

eBay expands managed shipping program amid seller eligibility concerns.

Peer Vergelijking

Prijswijziging

Takeda Pharmaceutical Co Ltd ADR Prognose

Koersdoel

By TipRanks

106.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 43.153 USD  106.37%

Hoogste 43.153 USD

Laagste 43.153 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Takeda Pharmaceutical Co Ltd ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat